Published in Elife on January 29, 2016
Anti-CD3 treatment up-regulates programmed cell death protein-1 expression on activated effector T cells and severely impairs their inflammatory capacity. Immunology (2017) 1.41
SATB1 Expression Governs Epigenetic Repression of PD-1 in Tumor-Reactive T Cells. Immunity (2017) 0.78
PD-L1 expression at tumor invasive front is associated with EMT and poor prognosis in esophageal squamous cell carcinoma. Cancer Sci (2017) 0.75
Prevention of allograft rejection in heart transplantation through concurrent gene silencing of TLR and Kinase signaling pathways. Sci Rep (2016) 0.75
PD-L1 serves as a double agent in separating GVL from GVHD. J Clin Invest (2017) 0.75
The Induction and Maintenance of Transplant Tolerance Engages Both Regulatory and Anergic CD4(+) T cells. Front Immunol (2017) 0.75
Harnessing Apoptotic Cells for Transplantation Tolerance: Current Status and Future Perspectives. Curr Transplant Rep (2017) 0.75
Blockade of only TGF-β 1 and 2 is sufficient to enhance the efficacy of vaccine and PD-1 checkpoint blockade immunotherapy. Oncoimmunology (2017) 0.75
Immunotherapy of WAP-TNP mice with early stage mammary gland tumors. Oncotarget (2017) 0.75
Restoring function in exhausted CD8 T cells during chronic viral infection. Nature (2005) 28.04
PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol (2008) 19.24
Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes. N Engl J Med (2005) 10.16
Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus. N Engl J Med (2002) 8.84
Effector and memory CD8+ T cell fate coupled by T-bet and eomesodermin. Nat Immunol (2005) 8.27
Control of effector CD8+ T cell function by the transcription factor Eomesodermin. Science (2003) 7.75
Effector and memory CTL differentiation. Annu Rev Immunol (2007) 7.17
T cell anergy. Annu Rev Immunol (2001) 7.15
Abrogation of TGFbeta signaling in T cells leads to spontaneous T cell differentiation and autoimmune disease. Immunity (2000) 6.97
Cell-autonomous Fas (CD95)/Fas-ligand interaction mediates activation-induced apoptosis in T-cell hybridomas. Nature (1995) 6.85
The PD-1 pathway in tolerance and autoimmunity. Immunol Rev (2010) 5.99
Interactions between PD-1 and PD-L1 promote tolerance by blocking the TCR-induced stop signal. Nat Immunol (2009) 5.20
Peripheral selection of the T cell repertoire. Science (1991) 4.56
TGF-beta-dependent mechanisms mediate restoration of self-tolerance induced by antibodies to CD3 in overt autoimmune diabetes. Nat Med (2003) 4.40
Teplizumab for treatment of type 1 diabetes (Protégé study): 1-year results from a randomised, placebo-controlled trial. Lancet (2011) 4.15
Transcriptional mechanisms underlying lymphocyte tolerance. Cell (2002) 4.04
Egr-2 and Egr-3 are negative regulators of T cell activation. Nat Immunol (2005) 3.74
Progenitor and terminal subsets of CD8+ T cells cooperate to contain chronic viral infection. Science (2012) 3.39
PDK1 regulation of mTOR and hypoxia-inducible factor 1 integrate metabolism and migration of CD8+ T cells. J Exp Med (2012) 2.58
The novel costimulatory programmed death ligand 1/B7.1 pathway is functional in inhibiting alloimmune responses in vivo. J Immunol (2011) 2.34
Cross-primed CD8(+) T cells mediate graft rejection via a distinct effector pathway. Nat Immunol (2002) 2.25
Transactivation by AP-1 is a molecular target of T cell clonal anergy. Science (1992) 2.25
Network analysis reveals centrally connected genes and pathways involved in CD8+ T cell exhaustion versus memory. Immunity (2012) 2.16
Visualizing the innate and adaptive immune responses underlying allograft rejection by two-photon microscopy. Nat Med (2011) 2.14
Fc-dependent depletion of activated T cells occurs through CD40L-specific antibody rather than costimulation blockade. Nat Med (2003) 1.92
Hypoxia-inducible factors enhance the effector responses of CD8(+) T cells to persistent antigen. Nat Immunol (2013) 1.86
Apoptosis within spontaneously accepted mouse liver allografts: evidence for deletion of cytotoxic T cells and implications for tolerance induction. J Immunol (1997) 1.81
Clonal anergy blocks in vivo growth of mature T cells and can be reversed in the absence of antigen. J Exp Med (1993) 1.69
Analysis of the role of negative T cell costimulatory pathways in CD4 and CD8 T cell-mediated alloimmune responses in vivo. J Immunol (2005) 1.62
Delayed anti-CD3 therapy results in depletion of alloreactive T cells and the dominance of Foxp3+ CD4+ graft infiltrating cells. Am J Transplant (2013) 1.52
Treatment of allograft recipients with donor-specific transfusion and anti-CD154 antibody leads to deletion of alloreactive CD8+ T cells and prolonged graft survival in a CTLA4-dependent manner. J Immunol (2000) 1.41
CD8 single-cell gene coexpression reveals three different effector types present at distinct phases of the immune response. J Exp Med (2007) 1.41
Formation of a bispecific antibody by the use of leucine zippers. J Immunol (1992) 1.37
Role of the PD-1 pathway in the immune response. Am J Transplant (2012) 1.35
In vivo anergized CD4+ T cells express perturbed AP-1 and NF-kappa B transcription factors. Proc Natl Acad Sci U S A (1996) 1.21
Peripheral deletional tolerance of alloreactive CD8 but not CD4 T cells is dependent on the PD-1/PD-L1 pathway. Blood (2008) 1.19
T-bet and Eomes are differentially linked to the exhausted phenotype of CD8+ T cells in HIV infection. PLoS Pathog (2014) 1.19
CXCR3 and its ligands in a murine model of obliterative bronchiolitis: regulation and function. J Immunol (2006) 1.12
Chronic HIV infection affects the expression of the 2 transcription factors required for CD8 T-cell differentiation into cytolytic effectors. Blood (2012) 1.02
An essential contribution by IFN-gamma to CD8+ T cell-mediated rejection of pancreatic islet allografts. J Immunol (2000) 0.96
Antigen-induced cell death of T effector cells in vitro proceeds via the Fas pathway, requires endogenous interferon-gamma and is independent of perforin and granzymes. Eur J Immunol (2002) 0.93
Direct versus indirect allorecognition: Visualization of dendritic cell distribution and interactions during rejection and tolerization. Am J Transplant (2006) 0.92
LAG-3, TGF-β, and cell-intrinsic PD-1 inhibitory pathways contribute to CD8 but not CD4 T-cell tolerance induced by allogeneic BMT with anti-CD40L. Blood (2011) 0.91
Induction of allograft tolerance by monoclonal CD3 antibodies: a matter of timing. Am J Transplant (2012) 0.91
Islet allograft rejection by contact-dependent CD8+ T cells: perforin and FasL play alternate but obligatory roles. Am J Transplant (2007) 0.90
The transcription cofactor Hopx is required for regulatory T cell function in dendritic cell-mediated peripheral T cell unresponsiveness. Nat Immunol (2010) 0.90
The structural bases of direct T-cell allorecognition: implications for T-cell-mediated transplant rejection. Immunol Cell Biol (2011) 0.87
CD2 rescues T cells from T-cell receptor/CD3 apoptosis: a role for the Fas/Fas-L system. Blood (1997) 0.86
Intragraft mechanisms associated with the immunosuppressive versus the tolerogenic effect of CD3 antibodies in a mouse model of islet allografts. Transplant Proc (2013) 0.77
Perivascular leukocyte clusters are essential for efficient activation of effector T cells in the skin. Nat Immunol (2014) 1.66
Costimulation via the tumor-necrosis factor receptor superfamily couples TCR signal strength to the thymic differentiation of regulatory T cells. Nat Immunol (2014) 1.25
Notch controls the survival of memory CD4+ T cells by regulating glucose uptake. Nat Med (2014) 1.14
Efficient norovirus and reovirus replication in the mouse intestine requires microfold (M) cells. J Virol (2014) 1.00
Thymus-derived regulatory T cells restrain pro-inflammatory Th1 responses by downregulating CD70 on dendritic cells. EMBO J (2015) 0.89
Impaired bone resorption and woven bone formation are associated with development of osteonecrosis of the jaw-like lesions by bisphosphonate and anti-receptor activator of NF-κB ligand antibody in mice. Am J Pathol (2014) 0.84
Bortezomib Improves Adoptive T-cell Therapy by Sensitizing Cancer Cells to FasL Cytotoxicity. Cancer Res (2015) 0.84
Vascular-resident CD169-positive monocytes and macrophages control neutrophil accumulation in the kidney with ischemia-reperfusion injury. J Am Soc Nephrol (2014) 0.84
Tumor Eradication by Cisplatin Is Sustained by CD80/86-Mediated Costimulation of CD8+ T Cells. Cancer Res (2016) 0.83
Myosin light chain kinase expression induced via tumor necrosis factor receptor 2 signaling in the epithelial cells regulates the development of colitis-associated carcinogenesis. PLoS One (2014) 0.82
CD27 Agonism Plus PD-1 Blockade Recapitulates CD4+ T-cell Help in Therapeutic Anticancer Vaccination. Cancer Res (2016) 0.81
Concomitant targeting of programmed death-1 (PD-1) and CD137 improves the efficacy of radiotherapy in a mouse model of human BRAFV600-mutant melanoma. Cancer Immunol Immunother (2016) 0.79
Blockade of PD-1/PD-L1 promotes adoptive T-cell immunotherapy in a tolerogenic environment. PLoS One (2015) 0.79
Macrophage Notch Ligand Delta-Like 4 Promotes Vein Graft Lesion Development: Implications for the Treatment of Vein Graft Failure. Arterioscler Thromb Vasc Biol (2015) 0.77
Sampling of Candida albicans and Candida tropicalis by Langerin-positive dendritic cells in mouse Peyer's patches. Immunol Lett (2015) 0.77
Endogenous Tim-1 promotes severe systemic autoimmunity and renal disease MRL-Fas(lpr) mice. Am J Physiol Renal Physiol (2014) 0.76
Systemic DC Activation Modulates the Tumor Microenvironment and Shapes the Long-Lived Tumor-Specific Memory Mediated by CD8+ T Cells. Cancer Res (2016) 0.76
Agonistic CD40 mAb-Driven IL12 Reverses Resistance to Anti-PD1 in a T-cell-Rich Tumor. Cancer Res (2016) 0.76
Pharmacologic inhibition of Notch signaling suppresses food antigen-induced mucosal mast cell hyperplasia. J Allergy Clin Immunol (2016) 0.76
SCIB1, a huIgG1 antibody DNA vaccination, combined with PD-1 blockade induced efficient therapy of poorly immunogenic tumors. Oncotarget (2016) 0.75
Agonists of the TRAIL Death Receptor DR5 Sensitize Intestinal Stem Cells to Chemotherapy-Induced Cell Death and Trigger Gastrointestinal Toxicity. Cancer Res (2015) 0.75
Notch Ligand DLL4 Alleviates Allergic Airway Inflammation via Induction of a Homeostatic Regulatory Pathway. Sci Rep (2017) 0.75
Identification of an immunogenic neo-epitope encoded by mouse sarcoma using CXCR3 ligand mRNAs as sensors. Oncoimmunology (2017) 0.75
Expansion of FasL-Expressing CD5(+) B Cells in Type 1 Diabetes Patients. Front Immunol (2017) 0.75
CD70 and IFN-1 selectively induce eomesodermin or T-bet and synergize to promote CD8(+) T-cell responses. Eur J Immunol (2015) 0.75
Editorial: Ying and Yang Members of the Tumor Necrosis Factor Superfamily: Friends or Foes in Immune-Mediated Diseases and Cancer. Front Immunol (2017) 0.75
Radiation-induced enhancement of antitumor T cell immunity by VEGF-targeted 4-1BB costimulation. Cancer Res (2017) 0.75
An agonistic anti-Toll-like receptor 4 monoclonal antibody as an effective adjuvant for cancer immunotherapy. Immunology (2019) 0.75
Rational Combination of Immunotherapies with Clinical Efficacy in Mice with Advanced Cancer. Cancer Immunol Res (2015) 0.75
Short-term cytokine stimulation reveals regulatory T-cells with down-regulated Foxp3 expression in human peripheral blood. Eur J Immunol (2017) 0.75
Autophagy-dependent regulation of tumor metastasis by myeloid cells. PLoS One (2017) 0.75
Common marmoset CD117+ hematopoietic cells possess multipotency. Int Immunol (2015) 0.75